Question 1

What is Roundtable 100?

Accepted Answer

Roundtable 100 is the weekly power ranking of the top 100 investable tech growth assets spanning crypto tokens, AI companies, and next-gen public markets. Rankings are published every Friday after market close and guided by a blue-ribbon committee of industry experts.

Question 2

What assets are included in the Roundtable 100?

Accepted Answer

The Roundtable 100 includes crypto tokens, public tech stocks with growth potential, and mining companies. It excludes legacy or slow-growth companies, private companies, and non-liquid investments.

Question 3

How are Roundtable 100 rankings scored?

Accepted Answer

Assets are scored across five dimensions: Safety (1x), Liquidity (1x), Leadership (1x), Innovation (1x), and Growth (2x double-weighted). Growth is intentionally double-weighted to reflect the mandate of identifying future dominance rather than present size.

Question 4

What is the Roundtable 100 investment thesis?

Accepted Answer

The Roundtable 100 focuses on long-term growth across public equities and cryptocurrencies with a 5+ year time horizon, investing in future-defining technologies and the critical systems that enable them — prioritizing assets that function as rails, bottlenecks, and structural constraints within emerging digital and industrial ecosystems.

Recursion

Clinical stage TechBio company

Recursion Announces New Clinical Data Across Two Potential First-in-Class Programs, Sanofi Partnership Milestone, and Oversubscribed $200M Offering

Najat Khan speaking at Quorum, a healthcare AI leaders forum co-hosted by Flare Capital Partners and Google for Startups

TechBio Talks: Breyer Capital's Morgan Cheatham with Host Najat Khan

Upcoming Presidential Plenary: Phase 1b/2 data for REC-4881 in FAP at CGA-IGC 2026

Where AI actually delivers in drug discovery with Dave Hallett

From data factory to better drugs: inside Recursion's AI-native product engine

How Recursion Is Using AI Agents to Design Better Drugs

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Recursion to Participate in Upcoming Investor Conferences

Recursion releases better, faster open source co-folding-based binding affinity model

Rewriting the Economics of Drug Discovery with Ben Taylor

New Model, AquaGen, Captures the Movement of Small Molecules

Recursion bridges translation gap with transcriptomic models

Recursion and Google Cloud case study

Recursion is advancing the first potential drug for rare disease FAP, discovered with AI